Acute lymphoblastic leukemia (ALL) has a high prevalence at early age and in children and regard to life expectancy index this disease cause to losing many years of life in these patients. Two well-known European protocols called United Kingdom (UK-ALL) and Berlin-Frankfurt-Munster (BFM-ALL) protocols are used to treat the disease in Iran, so the objective of this study is modelling of the treatment process using the protocols of BFM-ALL and UK-‎ALL to estimate more ‎cost-effectiveness method. A decision tree model was applied to depict the real treatment process to calculate costs per quality-adjusted life-year (QALY). Total costs were included to the model. The cost effectiveness ratio of UK-ALL is lower than BFM-ALL (1145.52 USD /3.87 QALY for UK-ALL and 1942.35 USD /3.02 QALY for BFM-ALL). Therefore, the UK-ALL is dominant and BFM-ALL is dominated.‎ The modeling results showed a double difference between the two studied options so policymakers and oncologist ‎should advocate the economic evaluation methods and modeling to select a real option in the treatment of patients to save resources like UK-ALL.